Cross-linked CMC and Silk Proteins in Eye Disease

D&V FARMA srl

Status: Completed

Conditions: Dry Eye Disease (DED)

Treatments: Device: CX-HA and CS

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06605365

COR-TF

Details and patient eligibility

About

Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market.

Both molecules have been widely studied for their viscoelastic and hydrating, and wound healing properties.

This new ophthalmic solution is the first on the market formulated with a CX-CMC and SP.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects affected by dry eye disease

Exclusion criteria

• know allergies to CX-CMC
• know allergies to SP

Trial design

20 participants in 1 patient group

CXC-SP

Description:

Subjects affected by dry eye disease are treated with the new ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP).

Treatment:

Device: CX-HA and CS